Schechter Investment Advisors LLC Has $670,000 Position in Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC lessened its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 25.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 90,044 shares of the biotechnology company’s stock after selling 30,358 shares during the period. Schechter Investment Advisors LLC’s holdings in Grifols were worth $670,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of GRFS. R Squared Ltd acquired a new position in shares of Grifols during the 4th quarter valued at $28,000. GAMMA Investing LLC grew its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares in the last quarter. Blue Trust Inc. grew its position in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares during the period. HighTower Advisors LLC grew its position in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,546 shares during the period. Finally, Tidal Investments LLC bought a new position in Grifols during the third quarter valued at about $147,000.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

NASDAQ GRFS opened at $8.27 on Wednesday. The company has a market cap of $5.69 billion, a PE ratio of 7.07 and a beta of 0.40. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $9.96. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The firm’s 50-day simple moving average is $7.43 and its two-hundred day simple moving average is $8.14.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.